Therefore, overexpression of LOXL2 and ZEB1 was confirmed, and simultaneous regulation of both could effectively inhibit the EMT process in gemcitabine-resistant pancreatic cancer. The gene discussed is LOXL2; the disease is familial pancreatic carcinoma.